Ironwood Pharmaceuticals, Inc. (FRA:I76)

Germany flag Germany · Delayed Price · Currency is EUR
3.200
0.00 (0.00%)
At close: Dec 4, 2025
-4.76%
Market Cap 486.64M
Revenue (ttm) 288.92M
Net Income (ttm) 24.33M
Shares Out n/a
EPS (ttm) 0.15
PE Ratio 20.00
Forward PE 6.42
Dividend n/a
Ex-Dividend Date n/a
Volume 3,878
Average Volume 1,177
Open 3.040
Previous Close 3.200
Day's Range 2.960 - 3.200
52-Week Range 0.478 - 4.520
Beta n/a
RSI 60.95
Earnings Date Feb 13, 2026

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-... [Read more]

Industry Pharmaceutical Preparations
Founded 1998
Employees 253
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol I76
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.